Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Single Blind Study of Ergoloid Mesylates, 5-Hydroxytryptophan, and the Combination in Adult Males With Fragile X Syndrome

NCT05030129 is registered in ClinicalTrials.gov with Elizabeth Berry-Kravis as lead sponsor.

NCT NCT05030129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05030129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Single Blind Study of Ergoloid Mesylates, 5-Hydroxytryptophan, and the Combination in Adult Males With Fragile X Syndrome
Lead sponsor
Elizabeth Berry-Kravis
Phase
Phase 2
Overall status
Completed
Start date
October 7, 2021
Completion date
January 19, 2023
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome